A study involving 85 patients with NSCLC demonstrated a significant correlation between the expression of exo-PD-L1 in serum and key clinical parameters, including tumor size, lymph node status, metastasis, and disease progression, highlighting its potential as a clinically relevant biomarker for NSCLC management (Li et al., 2019). Here, CD274 is linked to neoplasm.